A Global, Phase 3, Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 Mg (Triptorelin Mesylate Injection, 22.5 Mg) in Patients with Advanced Prostate Cancer (KATANA E6M)
Latest Information Update: 07 Feb 2025
Price :
$35 *
At a glance
- Drugs Triptorelin (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Foresee Pharmaceuticals
- 04 Feb 2025 New trial record